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Background and purpose   Osteochondral defects have a limited 
capacity for repair. We therefore investigated the effects of tumor 
necrosis  factor  (TNF)  signal  blockade  by  etanercept  (human 
recombinant soluble TNF receptor) on the repair of osteochon-
dral defects in rabbit knees.
Material and methods   Osteochondral defects (5 mm in diam-
eter) were created in the femoral patellar groove in rabbits. Soon 
after the procedure, a first subcutaneous injection of etanercept 
was performed. This single injection or, alternatively, 4 injections 
in total (twice a week for 2 weeks) were given. Each of these 2 
groups was divided further into 3 subgroups: a low-dose group 
(0.05 mg/kg), an intermediate-dose group (0.4 mg/kg), and a high-
dose group (1.6 mg /kg) with 19 rabbits in each. As a control, 19 
rabbits were injected with water alone. The rabbits in each sub-
group were killed 4 weeks (6 rabbits), 8 weeks (6 rabbits), or 24 
weeks (7 rabbits) after surgery and repair was assessed histologi-
cally.
Results   Histological examination revealed that the natural 
process of repair of the osteochondral defects was promoted by 
4 subcutaneous injections of intermediate-dose etanercept and 
by 1 or 4 injections of high-dose etanercept at the various time 
points examined postoperatively (4, 8, and 24 weeks). Western 
blot showed that rabbit TNFa had a high affinity for etanercept.
Interpretation   Blocking of TNF by etanercept enabled repair 
of osteochondral defects in rabbit knee. Anti-TNF therapy could 




Osteochondral  defects  have  a  limited  capacity  for  repair. 
Although the reason for this is still unclear, low progenitor 
cell numbers and/or low levels of growth factors are believed 
to play some part in this phenomenon. To promote repair, 
administration of various types of growth factors that func-
tion as anabolic factors—such as bone morphogenetic pro-
teins (BMPs) (Sellers et al. 1997), insulin-like growth factors 
(IGFs) (Singh et al. 2007), fibroblast growth factors (FGFs) 
(Ishii et al. 2007), and combinations of them (Martin et al. 
2001, Takahashi et al. 2005)—have been tested and found to 
be effective to some extent, though the effects of catabolic fac-
tors have not been well investigated.
Tumor necrosis factors (TNFs) and other pro-inflammatory 
cytokines are well-known catabolic factors in inflammation 
and tissue repair (Feldmann and Maini 1999, Goldberg et al. 
2007). Anti-TNF therapy has been applied to various types 
of serious inflammatory disease, such as rheumatoid arthri-
tis (Genovese et al. 2005), Crohn’s disease (Camilleri 2007), 
ankylosing spondylitis (Maksymowych et al. 2005), and spon-
dylarthropathy (Kruithof et al. 2005), as well as to degenera-
tive disease of the intervertebral disc (Autio et al. 2006). Anti-
TNF therapy is frequently used in patients with rheumatoid 
arthritis, and may promote regeneration of eroded joints (van 
der Heijde et al. 2006).
We evaluated the effects of subcutaneously injected etan-
ercept (soluble TNF receptor; p75) at various doses and after 
various  lengths  of  time  on  repair  of  5-mm  osteochondral 
defects made in the femoral patellar groove in rabbit knees.
Material and methods 
Operative procedure
We used 133 mature Japanese white rabbits (Japan SLC Co. 
Ltd., Hamamatsu, Japan) weighing 2.9 (2.7–3.0) kg. The aver-
age age was 24 weeks. They were anesthetized by intramus-
cular injection of a mixture of ketamine (100 mg/mL, 0.6 mL/
kg body weight) and xylazine (20 mg/mL, 0.3 mL/kg body 
weight). The patellar groove was exposed bilaterally through 
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ation of the patella. Osteochondral defects (5 mm diameter and 
5 mm depth) were created, and then the patella was reduced 
and the wound closed in layers. Each rabbit underwent sur-
gery in both knees simultaneously using the same procedure. 
Postoperatively, the animals were left uncasted and allowed 




Administration  of  etanercept  (Wyeth  Pharmaceuticals, 
Madison, NJ, USA) was performed in 2 different ways, with 
either 1 or 4 injections. One group had only 1 subcutaneous 
injection whereas the other group had 4 such injections. The 
first injection was performed soon after the operation in each 
group. 4 injections were performed twice a week for 2 weeks. 
In addition, to evaluate the dose-dependency of any effects of 
etanercept, we established 3 subgroups with different doses of 
etanercept in 0.5 mL distilled water: 0.05 μg /kg (the low-dose 
group), 0.4 μg /kg (the intermediate-dose group), and 1.6 μg /kg 
(the high-dose group). Animals in the control group received 
only 1 injection of 0.5 mL water, and not 4 injections, since we 
did not expect the findings to differ markedly between them. 
The rabbits in each subgroup were killed 4, 8, or 24 weeks 
after surgery (6, 6, and 7 rabbits, respectively), and repair was 
assessed histologically using a scoring system. 
Histological assessment
The rabbits were killed by excessive intravenous injection of 
anesthetic agents at each time point. The distal femurs were cut 
sagittally in the center of the patellar groove and fixed in 10% 
formaldehyde, decalcified in 10% ethylenediaminetetraacetic 
acid, embedded in paraffin wax, cut into sections of 5 μm, and 
stained with hematoxylin and eosin or toluidine blue.
For evaluation of osteochondral defect repair, we designed 
a new histological grading score (Table 1) by modifying the 
scoring  system  previously  reported  by  us  (Wakitani  et  al. 
1994).  It  involved  8  categories:  (A)  cell  morphology,  (B) 
matrix staining, (C) surface regularity, (D) thickness of the 
defect, (E) integration of repair tissue with the surrounding 
articular  cartilage,  (F)  arrangement  of  repair  cartilage,  (G) 
remodeling  of  subchondral  bone,  and  (H)  effects  on  adja-
cent cartilage. The scores ranged from 25 points for normal 
tissue to 0 points for poorest repair. Sections were examined 
blind and scored independently by 3 of the authors, without 
knowing which group was being examined.
Western blot of rabbit TNF-a
Anesthetized rabbits were administered 500 μg of lipopolysa- μg of lipopolysa-
charide (LPS; from E. coli serotype 026:B6; Sigma-Aldrich, 
St Louis, Mo, USA) in 500 μL PBS into the knee joints. 24 
h after LPS administration, the rabbits were anesthetized and 
synovial fluid was collected by aspiration. 
Collected synovial fluid was lysed in RIPA buffer containing 
1 mM phenylmethylsulfonyl fluoride (PMSF) and protease 
inhibitor cocktail at 50 μL/mL (Sigma-Aldrich). Samples were 
centrifuged for 15 min at 15,000 rpm and the supernatants were 
transferred to new tubes. Then tubes containing the supernatant   
with or without 25 μg of etanercept were gently rotated for 60 
min at 4ºC with 10 μL of a 50% slurry of Protein G Sepharose 
(Amersham Biosciences, Pittsburgh, PA, USA), which binds 
to the FC portion of etanercept and accelerates precipitation. 
After  the  treatment  with  or  without  etanercept,  the  tubes 
were centrifuged for 1 min at 2,000 rpm and the supernatants 
were transferred to new tubes. The precipitates and 20 μL of 
the supernatants were mixed with SDS polyacrylamide gel 
Table  1.  Histological  scoring  system  for  evaluation  of  repair  of 
osteochondral  defects.  This  was  a  modification  of  the  scoring 
system reported by Wakitani et al. (2002)
      Score
1) Features of repair cartilage
  A) Cell morphology    
    Hyaline cartilage     6
    Mostly hyaline cartilage  > 3/4  5
     Partly hyaline cartilage  1/4–3/4  4
    Mostly fibro-cartilage  > 3/4  3
    Partly fibro-cartilage  1/4–3/4  2
    Mostly non-cartilage    1
    None cartilage only    0
  B) Matrix staining (metachromasia)     
    Normal (compared to host)    4
     Slightly reduced staining  > 3/4  3
     Moderately reduced staining  1/4–3/4  2
     Remarkably reduced staining  < 1/4  1
     No metachromatic staining    0
  C) Surface regularity (total smooth area compared to the whole 
       area of the cartilage defect)
     Smooth  > 3/4  3
     Moderate  1/2–3/4  2
     Irregular  1/4–1/2  1
    Severe irregular  < 1/4  0
  D) Thickness of the defect (average thickness of reparative 
       cartilage compared to that of surrounding cartilage)
    Normal  > 2/3  2
    Moderate  1/3–2/3  1
    Thin  < 1/3  0
  E) Integration of repair tissue to the surrounding articular cartilage
    Both edges integrated    2
    One edge integrated    1
    Both edges not integrated    0
  F) Arrangement of repair cartilage
    Column-like arrangement    2
    Partly column-like arrangement    1
    Disordered    0
2) Features of surrounding tissue
  G) Remodeling of subchondral bone
    Complete reconstruction    3
    Continuous but incomplete reconstruction  2
    Discontinuous, greater than 50% reconstruction  1
    Discontinuous, less than 50% reconstruction  0
  H) Effect on adjacent cartilage (toluidine blue staining of adjacent 
       cartilage adjacent to the edge of the defect) 
        Normal (compared to host)    3
    Slightly reduced staining  > 3/4  2
    Remarkably reduced staining  1/4–3/4  1
    Little or no metachromatic staining  < 1/4  0608  Acta Orthopaedica 2009; 80 (5): 606–611
electrophoresis (PAGE) buffer and boiled for 10 min, then 
applied to each lane of a 4–20% SDS polyacrylamide gel (20 
mA, low voltage for 90 min), and ultimately transferred to 
Immobilon-P PVDF membrane (Millipore). The membrane 
was blocked for 1 hour at room temperature with 5% skim 
milk  (Difco)  in  Tris-buffered  saline  (TBS)  followed  by 
washing with TBS containing 0.1% Tween 20 (TBST) for 
15 min; it was then incubated overnight with goat anti-rabbit 
TNF-a antibody (1:50 in blocking buffer; Fitzgerald Industries 
International,  Concord,  MA,  USA)  at  4ºC.  After  washing 
twice with TBST for 15 min, the membrane was incubated 
with peroxidase-conjugated rabbit anti-goat antibody (1:500; 
Dako, Glostrup, Denmark) for 30 min. After washing twice 
again with TBST for 15 min, the membrane was developed 
with ECL Plus reagent (Amersham Biosciences).
Statistics
Differences in histological score between the control group 
and each etanercept treatment group at various time points 
postoperatively (4, 8, and 24 weeks) were tested by the post 




4 weeks after surgery the defects were found to be covered 
with fibrous tissue, with partial and weak metachromasia in 
the control group. In all the etanercept groups, especially in 
the intermediate and high-dose subgroups that received either 
1 or 4 injections, metachromasia was wider and stronger than 
in the control group. Repair of subchondral bones was better 
in all etanercept groups than in the control group (Figure 1). 
These findings suggest that etanercept promoted early sub-
chondral bone remodeling of osteochondral defects.
8 weeks after surgery, the defects were covered with fibrous 
tissue with partial metachromasia, and they were thinner than 
those at 4 weeks. Subchondral bone repair had been promoted 
in all groups, including the control group. Repair was good 
with 1 injection in the high-dose subgroup, though in the other 
groups there were no discernible differences in repair from 
that in the control group (data not shown).
24  weeks  after  surgery,  repair  of  subchondral  bone  was 
almost complete, and the repaired cartilage was slightly thin-
ner than the adjacent normal cartilage (Figure 2). The cell 
morphology and matrix staining indicated good repair with 4 
injections in the intermediate and high-dose subgroups.
Figure 1. Representative histological images of osteochondral defects after 4 weeks, stained 
with toluidine blue (magnification ×20). A: control group; B: 1 injection, low dose; C: 1 injection, 
intermediate dose; D: 1 injection, high dose; E: 4 injections, low dose; F: 4 injections, intermedi-
ate dose; G: 4 injections, high dose. Large areas of metachromatic staining were observed in 
C, D, E, F, and G.
  A   B   C
  D   E   F
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On histological evaluation of some samples in the interme-
diate and high-dose subgroups, promotion of repair was so 
dramatic that the repair tissue looked almost like complete 
hyaline cartilage histologically. 
Adjacent cartilage did not show any degeneration in any 
of the samples examined, indicating that etanercept does not 
affect metabolism of normal cartilage. 
Histological scoring system
The differences in histological scores in the control group and 
in the 6 different subgroups at various time points postopera-
reduced  at  the  same  time.  These  findings  confirmed  that 
etanercept has a substantial affinity for rabbit intra-articular 
TNF-a.
Discussion
The natural process of repair of 5-mm osteochondral defects 
in the patellar groove of rabbit knees was promoted by 4 sub-
cutaneous injections of intermediate-dose etanercept and by 
1 or 4 injections of high-dose etanercept at the various time 
Figure 2. Representative histological images of osteochondral defects after 24 weeks, stained 
with toluidine blue (magnification ×20). A: control group; B: 1 injection, low dose; C: 1 injection, 
intermediate dose; D: 1 injection, high dose; E: 4 injections, low dose; F: 4 injections, inter-
mediate dose; G: 4 injections, high dose. Nearly complete subchondral bone remodeling and 
continuous cartilage regeneration were found in F and G, while subchondral bone remodeling 
remained discontinuous in A, B, and C. 
  A   B   C
  D   E   F
  G
Table 2. Histological scores by group. Figures are mean (SD) 
Dose  No. of   Overall   4 weeks   8 weeks  24 weeks
  injections  difference  (6 rabbits)  (6 rabbits)  (7 rabbits)
Control  1    14 (1.1)  14 (3.0)  14 (3.5)
Low  1  none  15 (2.8)  15 (2.4)  16 (3.8)
  4  none  13 (3.4)  13 (3.9)  13 (3.3)
Intermediate  1  none  17 (1.8)   16 (4.2)  14 (3.4)
  4  yes  16 (2.0)   17 (5.2)  19 (2.3)
High  1  yes  17 (2.6)   19 (3.7)  16 (2.6)
  4  yes   16 (2.7)   17 (1.1)  18 (3.6) 
tively (4, 8, and 24 weeks) showed statistically 
significantly better repair with 4 injections in 
the intermediate-dose subgroup and 1 and 4 
injections in the high-dose subgroups than in 
the other groups (Table 2). 
Western blot
Western  blot  analysis  indicated  that  the 
synovial fluid from joints with LPS-induced 
arthritis contained TNF-a (Figure 3). When we 
treated the samples with etanercept, the TNF-
a  present  in  precipitates  was  dramatically 
increased  while  that  in  supernatants  was 610  Acta Orthopaedica 2009; 80 (5): 606–611
points examined postoperatively. The repair process was pro-
moted even with 1 injection just after surgery, indicating that 
blocking of TNFs early on in the repair process is important. 
However, histological examination at 24 weeks showed that 
4 injections were more effective than 1 injection. These find-
ings suggest that TNFs are involved in the process of cartilage 
and subchondral bone repair at least 2 weeks after creation 
of defects, and that blockade of TNFs in this period leads to 
better repair of defects. We assumed that TNFs exhibit effects 
early after the creation of defects, and we therefore decided to 
block TNF activity in the first 2 weeks. Because we hypoth-
esized that TNFs might show effects early within the 2-week 
postoperative period, we included 1-injection groups. We did 
not include groups that received etanercept injection for more 
than 2 weeks. Further investigation may be required to deter-
mine the appropriate period of etanercept administration.
This study revealed dose-dependent effects of etanercept 
on the process of repair of osteochondral defects in the rabbit 
knee. The intermediate dose of etanercept was 40 μg/kg, which 
approximately matches the clinically used dose in humans (2.5 
mg) assuming an average human body weight of 60 kg. On 
the other hand, administration of 160 μg/kg in the high-dose 
subgroups, equivalent to 9.6 mg in humans and thus corre-
sponding to administration of an overdose, showed effects on 
cartilage repair similar to those seen in the intermediate-dose 
subgroups, while the low dose (5 μ/kg)—equivalent to 0.3 mg 
in humans—had only limited effects.
When  tissues  are  injured,  catabolic  cytokines  including 
TNFs are released, evoke inflammation, and function in the 
removal of destroyed tissue. However, it is likely that strong 
inflammation  interferes  with  tissue  repair.  Previous  stud-
ies have revealed enhancement of repair by inhibition of the 
effects of TNFs on bone formation in vivo and in vitro (Hashi-
moto et al. 1989, Zhou et al. 2006) and on meniscus in vitro 
(McNulty et al. 2007). As found in our study, an antagonist of 
TNFs promoted repair of osteochondral defects. TNFs may 
interfere with the mobilization, proliferation, and/or differen-
tiation of mesenchymal osteochondro-progenitor cells, though 
their contribution to cartilage and bone repair is controversial 
(Fukui et al. 2006)
Our scoring system was a modified version of a system pre-
viously reported for the evaluation of rabbit osteochondral 
defect repair. The principal modifications we made concerned 
remodeling  of  subchondral  bone  and  degenerative  change 
in adjacent normal cartilage, which are important factors in 
histological evaluation of cartilage repair. Complete remodel-
ing of subchondral bone is necessary for cartilage repair, both 
mechanically and biologically. It is important to determine 
whether operative procedures and drugs affect not only repair 
of tissue but also adjacent normal cartilage. It is important to 
emphasize that good reconstruction of subchondral bone was 
obtained at 4 weeks with both 1 and 4 injections in the inter-
mediate and high-dose subgroups. It appears that blocking of 
TNFs may be more effective in improving bone repair than 
cartilage repair at 4 weeks. The International Cartilage Repair 
Society (ICRS) cartilage repair assessment score (O’Driscoll 
et al. 1988) was established for clinical use, but is not good for 
small animal experiments. This system is for assessment by 
arthroscopic appearance and cannot be used for assessment of 
subchondral bone and matrix staining of the adjacent normal 
cartilage.
Our findings suggest that cytokine therapy may be useful for 
promoting cartilage repair. Bone marrow-stimulating opera-
tive procedures such as abrasion, drilling, and microfracture 
(Kreuz  et  al.  2006)  and  tissue  engineering  techniques  are 
sometimes performed in patients with osteoarthritis or osteo-
chondritis dissecans (Wakitani et al. 2002), and blocking of 
TNF  activity  may  promote  cartilage  repair  in  conjunction 
with these techniques. The dosage of TNF-blocking agents is 
of importance, since our findings indicate that incorrect dos-
ages may result in insufficient cartilage repair or in adverse 
effects.
Small defects less than 3 mm wide have been reported to be 
spontaneously repaired in rabbits (Lietman et al. 2002). We 
made osteochondral defects 5 mm in diameter and 5 mm deep 
in large, fully mature rabbits since it appeared that this might 
enhance differences in therapeutic effects between the condi-
tions studied. The control group did not exhibit repair.
There are 2 receptors for TNFs, p55 and p75. Etanercept is 
the soluble TNF receptor, p75, which binds to both TNF-a 
and TNF-β in humans. There have been no previous reports 
that etanercept binds to rabbit TNFs. Here we found that etan-
ercept binds to rabbit TNF-a.
It may be possible to use etanercept, systemically or locally, 
in the repair of osteochondral defects in humans. However, 
because our study was a preliminary one using a rabbit model, 
further experiments will be necessary to confirm the useful-
ness of etanercept in promoting the repair of osteochondral 
defects in humans.
Figure 3. Western blot of TNF-a. Samples were prepared from LPS-
induced synovial fluids with or without eternacept (right-hand and left-
hand lanes, respectively). Precipitates (upper panel) and supernatants 
(lower panel) of each sample were separated by SDS-PAGE and the 
presence of TNF-a detected by sandwich technique using polyclonal 
antibodies.Acta Orthopaedica 2009; 80 (5): 606–611  611
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